FUJISAWA's PROGRAF WILL BE AVAILABLE BY EARLY JUNE FOLLOWING APPROVAL FOR LIVER TRANSPLANT REJECTION PREVENTION; POST- TRANSPLANT DOSING MAY BE ADVANTAGE
Executive Summary
Fujisawa will begin marketing Prograf to liver transplant centers in early June. The first immunosuppressant for the prevention of organ transplant rejection to be approved in over 10 years, Prograf (tacrolimus/FK506) cleared FDA on April 8 ("The Pink Sheet" April 11, T&G-1).